Anthracyclines are the most commonly prescribed chemotherapeutic agent for their effectiveness in treating cancer. However use of anthracyclines can have the severe, adverse effect of cardiac toxicity leading to cardiomyopathy and clinical heart failure. Currently available medications to counteract anthracycline-induced cardiotoxicity either do so at the cost of anti-tumor activity, or there is insufficient clinical trial data to support their efficacy in preventing cardiotoxicity. Thus widespread use of these compounds is limited.
There is a clinical need for a pharmaceutical compound that can prevent and/or treat the cardiac side effects of anthracyclines while maintaining their anti-tumor activity.
Researchers at UCSF have found that optimal dosing of an established and specific alpha-1-adrenergic receptor agonist, known as A61603, results in cardioprotective properties in an in vivo mouse model of anthracycline-induced cardiotoxicity, using the most common anthracycline, doxorubicin. Administration of A61603 led to increased survival and improved indices of cardiac damage. The low dose of A61603 was able to provide a beneficial reduction in cardiotoxicity without increasing blood pressure.
Furthermore, targeting of the alpha-1-adrenergic receptor in cardiotoxicity is validated by studies of cardiac myocytes in vitro, and by preliminary data in other mouse in vivo heart disease models.
For more detailed information, please refer to U.S. Patent Application No. 12/610,720.
The investigators are currently also studying beneficial uses of A61603 in other disease indications.
|United States Of America||Issued Patent||9,364,462||06/14/2016||2012-207|
|United States Of America||Issued Patent||8,778,897||07/15/2014||2012-207|
|United States Of America||Issued Patent||8,324,178||12/04/2012||2012-207|